Comparative Study of Diffuse Large B-Cell Lymphoma and Reactive Lymphoid Hyperplasia Lymph Node Derived Mesenchymal Stem Cells.
10.19746/j.cnki.issn.1009-2137.2025.05.040
- Author:
Yu-Shuo MA
1
;
Zhi-He LIU
1
;
Yang SUN
2
;
Yu-Hang ZHANG
1
;
Wen-Qiu WANG
1
;
Li-Sheng WANG
2
;
Xia ZHAO
1
Author Information
1. Department of Hematology, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
2. Laboratory of Molecular Diagnosis and Regenerative Medicine, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
- Publication Type:English Abstract
- Keywords:
diffuse large B-cell lymphoma;
mesenchymal stem cell;
transcriptome sequencing;
tumor microenvironment
- MeSH:
Humans;
Mesenchymal Stem Cells/cytology*;
Lymphoma, Large B-Cell, Diffuse/pathology*;
Cell Differentiation;
Lymph Nodes/pathology*;
Pseudolymphoma/pathology*
- From:
Journal of Experimental Hematology
2025;33(5):1516-1523
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the biological behavior, differentiation ability, and differential gene expression of lymph node mesenchymal stem cells (MSCs) in patients with diffuse large B-cell lymphoma (DLBCL) and reactive lymphoid hyperplasia (RLH), providing a theoretical basis for clinical chemotherapy resistance.
METHODS:Lymph node MSCs from patients with DLBCL and RLH were separated, passaged and cultured. The cell morphology and growth status were observed. Flow cytometry was performed to detect the immune phenotype of MSCs. The in vitro directed differentiation ability of the two types of MSCs was observed. High-throughput sequencing was used to analyze the differential gene expression and enrichment of two groups of MSCs.
RESULTS:The lymph node MSCs of patients with DLBCL and RLH had similar cell morphology and growth characteristics, and both groups of MSCs expressed CD90, CD105, and CD73 on the cell surface. Compared with lymph node MSCs derived from patients with RLH, lymph node MSCs derived from DLBCL patients showed stronger osteogenic and adipogenic differentiation abilities. High-throughput sequencing results displayed that lymph node MSCs derived from DLBCL patients significantly upregulated some genes such as TOP2A, LFNG, GRIA3, SEC14L2, SPON2, AURKA, LRRC15, FOXD1, HOXC9, CDC20 and remarkably downregulated some genes such as TBC1D8, LDLR, PCDHAC2, POLH, PKP2, ANKRD37, DMKN, HSD11B1, ARHGAP20, PTGS1,etc.
CONCLUSION:Lymph node MSCs in DLBCL patients exhibit unique biological behavior and gene expression profiles, which may be closely related to clinical chemotherapy resistance.
